Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorM.D. Anderson Cancer Center
About this trial
This study collects information about complications and clinical response in cancer patients treated with anti-VEGF-related therapies. This study aims to observe side effects that may happen to patients with advanced cancer who are treated with anti-VEGF related therapy. This may help doctors learn if there are any relationships between these side effects and how the disease may respond to treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients must be able to understand and be willing to sign a written informed consent document
Patients must be receiving any anti-VEGF-related regimen in monotherapy or combination therapy
Disqualifiers
None
Trial population
Patients receiving any anti-VEGF-related regimen
Trial design
Design model
Case-only
Time perspective
Other
Treatments tested in this trial
Electronic Health Record Review
Other interventionMedical records are reviewed
Treatment groups
170 Participants
are divided into 1 treatment groupGroup A: Observational (medical records review)1 intervention
Trial outcomes
Primary outcomes
1
Incidence of grade 3+ adverse events (AE) at least possibly related to anti-VEGF-related treatment (overall and each type separately)
For each toxicity, will estimate the odds ratio, associated 95% confidence interval and p-value.
Time frame
Up to 5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov